SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $366,457,132 |
| Positions | 20 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| CG ONCOLOGY INC | CGON | COM | $80,393,115 | 1,131,500 |
| UROGEN PHARMA LTD | URGN | COM | $61,581,856 | 1,673,420 |
| TREVI THERAPEUTICS INC | TRVI | COM | $40,001,341 | 2,144,844 |
| CANDEL THERAPEUTICS INC | CADL | COM | $36,028,864 | 3,497,948 |
| PUMA BIOTECHNOLOGY INC | PBYI | COM | $33,504,835 | 4,131,299 |
| JADE BIOSCEINCES INC | JBIO | COM NEW | $21,925,807 | 986,760 |
| BICARA THERAPEUTICS | BCAX | COM | $19,102,000 | 643,381 |
| KARYOPHARM THERAPEUTICS INC | KPTI | COMMON STOCK | $14,831,964 | 1,518,113 |
| ONKURE THERAPEUTICS INC | OKUR | CLASS A COM | $12,948,913 | 2,839,674 |
| HELUS PHARMA INC. | HELP | COM STK | $10,181,159 | 1,540,266 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.